Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score
Autor: | Minh-Phuong, Huynh-Le, Roshan, Karunamuni, Chun Chieh, Fan, Lui, Asona, Wesley K, Thompson, Maria Elena, Martinez, Rosalind A, Eeles, Zsofia, Kote-Jarai, Kenneth R, Muir, Artitaya, Lophatananon, Johanna, Schleutker, Nora, Pashayan, Jyotsna, Batra, Henrik, Grönberg, David E, Neal, Børge G, Nordestgaard, Catherine M, Tangen, Robert J, MacInnis, Alicja, Wolk, Demetrius, Albanes, Christopher A, Haiman, Ruth C, Travis, William J, Blot, Janet L, Stanford, Lorelei A, Mucci, Catharine M L, West, Sune F, Nielsen, Adam S, Kibel, Olivier, Cussenot, Sonja I, Berndt, Stella, Koutros, Karina Dalsgaard, Sørensen, Cezary, Cybulski, Eli Marie, Grindedal, Florence, Menegaux, Jong Y, Park, Sue A, Ingles, Christiane, Maier, Robert J, Hamilton, Barry S, Rosenstein, Yong-Jie, Lu, Stephen, Watya, Ana, Vega, Manolis, Kogevinas, Fredrik, Wiklund, Kathryn L, Penney, Chad D, Huff, Manuel R, Teixeira, Luc, Multigner, Robin J, Leach, Hermann, Brenner, Esther M, John, Radka, Kaneva, Christopher J, Logothetis, Susan L, Neuhausen, Kim, De Ruyck, Piet, Ost, Azad, Razack, Lisa F, Newcomb, Jay H, Fowke, Marija, Gamulin, Aswin, Abraham, Frank, Claessens, Jose Esteban, Castelao, Paul A, Townsend, Dana C, Crawford, Gyorgy, Petrovics, Ron H N, van Schaik, Marie-Élise, Parent, Jennifer J, Hu, Wei, Zheng, Ian G, Mills, Ole A, Andreassen, Anders M, Dale, Tyler M, Seibert |
---|---|
Přispěvatelé: | collaborators, UKGPCS, BioResource), APCB (Australian Prostate Cancer, Investigators, NC-LA PCaP, Collaborators, IMPACT Study Steering Committee and, Investigators, Canary PASS, Committee, Profile Study Steering, Consortium, PRACTICAL, Clinical Chemistry |
Jazyk: | angličtina |
Rok vydání: | 2022 |
Předmět: |
SELECTION
Male Cancer Research Urology LASSO Polymorphism Single Nucleotide Risk Assessment Cancer screening Cancer epidemiology SDG 3 - Good Health and Well-being Risk Factors Humans Genetic Predisposition to Disease prostate cancer multi-ancestry datasets Cancer genetics Early Detection of Cancer Prostatic Neoplasms/diagnosis Cancer och onkologi Science & Technology Manchester Cancer Research Centre ResearchInstitutes_Networks_Beacons/mcrc Prostatic Neoplasms Urology & Nephrology Prostate-Specific Antigen Prostate-Specific Antigen/genetics Oncology Cancer and Oncology Life Sciences & Biomedicine |
Zdroj: | Huynh-Le, M-P, Karunamuni, R, Fan, C C, Asona, L, Thompson, W K, Martinez, M E, Eeles, R A, Kote-Jarai, Z, Muir, K R, Lophatananon, A, Schleutker, J, Pashayan, N, Batra, J, Grönberg, H, Neal, D E, Nordestgaard, B G, Tangen, C M, MacInnis, R J, Wolk, A, Albanes, D, Haiman, C A, Travis, R C, Blot, W J, Stanford, J L, Mucci, L A, West, C M L, Nielsen, S F, Kibel, A S, Cussenot, O, Berndt, S I, Koutros, S, Sørensen, K D, Cybulski, C, Grindedal, E M, Menegaux, F, Park, J Y, Ingles, S A, Maier, C, Hamilton, R J, Rosenstein, B S, Lu, Y-J, Watya, S, Vega, A, Kogevinas, M, Wiklund, F, Penney, K L, Huff, C D, Teixeira, M R, Multigner, L, Leach, R J & UKGPCS collaborators 2022, ' Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score ', Prostate Cancer and Prostatic Diseases, vol. 25, no. 4, pp. 755-761 . https://doi.org/10.1038/s41391-022-00497-7 Prostate Cancer and Prostatic Diseases, 25(4), 755-761. Nature Publishing Group UKGPCS Collaborators 2022, ' Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score ', Prostate Cancer and Prostatic Diseases . https://doi.org/10.1038/s41391-022-00497-7 Minh-Phuong Huynh-Le, Karunamuni, R, Fan, C C, Asona, L, Thompson, W K, Martinez, M E, Eeles, R A, Kote-Jarai, Z, Muir, K R, Lophatananon, A, Schleutker, J, Pashayan, N, Batra, J, Groenberg, H, Neal, D E, Nordestgaard, B G, Tangen, C M, MacInnis, R J, Wolk, A, Albanes, D, Haiman, C A, Travis, R C, Blot, W J, Stanford, J L, Mucci, L A, West, C M L, Nielsen, S F, Kibel, A S, Cussenot, O, Berndt, S, Koutros, S, Sorensen, K D, Cybulski, C, Grindedal, E M, Menegaux, F, Park, J Y, Ingles, S A, Maier, C, Hamilton, R J, Rosenstein, B S, Lu, Y-J, Watya, S, Vega, A, Kogevinas, M, Wiklund, F, Penney, K L, Huff, C D, Teixeira, M R, Multigner, L, Leach, R J, UKGPCS Collaborators, APCB Australian Prostate Canc BioR, NC-LA PCaP Investigators, IMPACT Study Steering Comm Collabo, Canary PASS Investigators, Profile Study Steering Comm & PRACTICAL consortium 2022, ' Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score ', Prostate Cancer and Prostatic Diseases, vol. 25, pp. 755–761 . https://doi.org/10.1038/s41391-022-00497-7 |
ISSN: | 1365-7852 |
DOI: | 10.1038/s41391-022-00497-7 |
Popis: | Background Prostate cancer risk stratification using single-nucleotide polymorphisms (SNPs) demonstrates considerable promise in men of European, Asian, and African genetic ancestries, but there is still need for increased accuracy. We evaluated whether including additional SNPs in a prostate cancer polygenic hazard score (PHS) would improve associations with clinically significant prostate cancer in multi-ancestry datasets. Methods In total, 299 SNPs previously associated with prostate cancer were evaluated for inclusion in a new PHS, using a LASSO-regularized Cox proportional hazards model in a training dataset of 72,181 men from the PRACTICAL Consortium. The PHS model was evaluated in four testing datasets: African ancestry, Asian ancestry, and two of European Ancestry—the Cohort of Swedish Men (COSM) and the ProtecT study. Hazard ratios (HRs) were estimated to compare men with high versus low PHS for association with clinically significant, with any, and with fatal prostate cancer. The impact of genetic risk stratification on the positive predictive value (PPV) of PSA testing for clinically significant prostate cancer was also measured. Results The final model (PHS290) had 290 SNPs with non-zero coefficients. Comparing, for example, the highest and lowest quintiles of PHS290, the hazard ratios (HRs) for clinically significant prostate cancer were 13.73 [95% CI: 12.43–15.16] in ProtecT, 7.07 [6.58–7.60] in African ancestry, 10.31 [9.58–11.11] in Asian ancestry, and 11.18 [10.34–12.09] in COSM. Similar results were seen for association with any and fatal prostate cancer. Without PHS stratification, the PPV of PSA testing for clinically significant prostate cancer in ProtecT was 0.12 (0.11–0.14). For the top 20% and top 5% of PHS290, the PPV of PSA testing was 0.19 (0.15–0.22) and 0.26 (0.19–0.33), respectively. Conclusions We demonstrate better genetic risk stratification for clinically significant prostate cancer than prior versions of PHS in multi-ancestry datasets. This is promising for implementing precision-medicine approaches to prostate cancer screening decisions in diverse populations. |
Databáze: | OpenAIRE |
Externí odkaz: |